Safety and efficacy of the use of institutional unfractionated heparin protocols for therapeutic anticoagulation in obese patients: a retrospective chart review.

Shin, Sooyoung; Harthan, Elizabeth F
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
2015Sep ; 26 ( 6 ) :655-60.
PMID : 26236941
ÀúÀÚ »ó¼¼Á¤º¸
Shin, Sooyoung -
Harthan, Elizabeth F -
ABSTRACT
Obesity is an independent risk factor for venous thromboembolism and ischemic heart disease. Optimal dosing strategies for heparin in obese patients are limited, as this population is mostly underrepresented in clinical trials. We evaluated the therapeutic efficacy and safety of unfractionated heparin dosing protocols when used in obese patients. A retrospective review of treatment effects was performed to analyse patient specific data regarding the use of therapeutic heparin in patients divided into four weight groups (<100, 100 to <125, 125 to <150 and ??50?kg). Patients received heparin via the dosing protocols approved by the institution's Pharmacy and Therapeutics (P&T) committee. Demographics, heparin protocol used, heparin dosage, therapy duration, laboratory values and indicators for bleeding complications were reviewed for adult patients receiving heparin for more than 48?h. Two hundred and forty patients were analysed, including 60 patients in each weight group. A significant difference was found across the groups in time to therapeutic activated partial thromboplastin time (aPTT) (P?=?0.002) and mean heparin dosage at first therapeutic aPTT based on total body weight (units/kg per h) (P?
na
MESH
Anticoagulants/*therapeutic use, Female, Heparin/adverse effects/*therapeutic use, Humans, Male, Obesity/*drug therapy, Retrospective Studies, Risk Factors
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
When comparing length of UFH therapy across the weight groups, the duration was significantly longer in the larger weight groups than the less than 100 kg control group, P = 0.031
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1097/MBC.0000000000000336.
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå